TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 positive by licensed diagnostic test with presumed duration of infection \> 6 months from date of randomisation.~* Aged \> 16 years of age (or minimum age as determined by local regulations or as legal requirements dictate).~* Antiretroviral treatment naïve.~* Qualifying plasma HIV RNA \> 2,000 copies/mL and a CD4+ T cell count of ≥ 50 cells/µL.~* No evidence of harbouring a drug resistant HIV (based upon genotypic drug testing).~* Calculated creatinine clearance (CLCr) greater than or equal to 70 mL/min (Cockcroft-Gault formula).~* Able to provide written informed consent.~Exclusion Criteria:~* The following laboratory variables,~  * absolute neutrophil count (ANC) \< 750 cells/µL~ * haemoglobin \< 8.0 g/dL~ * platelet count \< 50,000 cells/µL~ * serum AST, ALT \> 5 x upper limit of normal (ULN)~ * serum bilirubin \> 1.5 x ULN~* Pregnant or nursing mothers.~* Current use of human growth hormone, testosterone or other anabolic steroid.~* Current use of any prohibited medications as described in product specific information.~* Acute therapy for serious infection or other serious medical illness (in the judgement of the site Principal Investigator) requiring systemic treatment and/or hospitalisation.~* Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the trial.~* Patients unlikely to be able to remain in follow-up for the protocol-defined period.~* Patients with known renal insufficiency.~* Patients with obstructive liver disease.~* Patients with intractable diarrhoea (six loose stools/day for at least seven consecutive days).~* History of acute or chronic pancreatitis.~* Presence of cardiomyopathy (due to any cause) or any significant cardiovascular disease, such as unstable ischemic heart disease.~* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated).

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)
- 2 (Type: ACTIVE_COMPARATOR): Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
- 3 (Type: EXPERIMENTAL): Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent had to be obtained prior to participation in the study.~2. Patients on established lipid lowering medication or, have been recommended lipid lowering therapy by their health care provider but were unable to tolerate treatment.~3. A total cholesterol measurement at screening that was ≥4 mmol/L \[approximately 160 mg/dL\].~4. Participants on lipid-lowering therapies had to be on a stable dose for ≥30 days before screening with no planned medication or dose change.~Exclusion Criteria:~1. Medical or surgical history that might limit the individual's ability to take study treatments for the duration of the study and/or put the participant at significant risk .~2. Current or planned renal dialysis or transplantation.~3. Acute coronary syndrome or stroke less than 4 weeks before the screening visit.~4. Coronary revascularization procedure planned within the next 6 months.~5. Women of child-bearing potential, unless they agree to abstinence or, if sexually active, agree to the use of effective methods of contraception during the study.~6. Women who are pregnant or breast-feeding.~7. Previous, current or planned treatment with a monoclonal antibody targeting PCSK9, or with a drug known to be contra-indicated with inclisiran.~8. Previous exposure to inclisiran or participation in a randomised study of inclisiran.~9. Current or previous participation in a clinical study with an unlicensed drug or device within 30 days or five half-lives of the screening visit, whichever is longer.~10. Participants who planed to move away from the geographical area where the study is being conducted during the study period.~11. A triglyceride measurement at screening that is greater than or equal to 4.52 mmol/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control+ BS (Type: ACTIVE_COMPARATOR): Participants continued to receive their background lipid lowering therapy plus behavioural support (BS).
- Inclisiran (Type: EXPERIMENTAL): Participants continue to receive their background lipid lowering therapy, plus inclisiran for injection (delivered in an injection-only model).
- Inclisiran + BS (Type: EXPERIMENTAL): Participants continued to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who require continuous NSAID therapy during the treatment period with the study drug~2. Participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed~3. Outpatient (including inpatient for examinations)~Exclusion Criteria:~1. Participants scheduled to change the type and dosage regimen of NSAID~2. Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed~3. Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology~4. Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery~5. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders~6. Participants with a previous or current history of aspirin-induced asthma

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-438 10 mg QD (Type: EXPERIMENTAL): None
- TAK-438 20 mg QD (Type: EXPERIMENTAL): None
- Lansoprazole 15 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who can provide an assent form signed by themselves and informed consent form by their legal representatives prior to performing of any study procedures.~2. Male or female children and adolescents aged 6 to 18 years~3. Patients who are diagnosed with chronic tic disorders(Motor or Phonic) or Tourette's disorder according to DSM-IV(Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition)(using K-SADS-PL-K (Kiddle-Schedule for Affective Disorders and Schizophrenia,Present and Lifetime Version-Korean version)) and require drug therapy.~4. The total tic score of the K-YGTSS (Korean version of Yale Global Tic Severity Scale)is more than 22 at baseline~Exclusion Criteria:~1. Patients with secondary tic symptoms accompanied by Tardive tics, Huntington disease, neuroacanthocytosis, mental retardation, or autism~2. Patients with IQ (Intelligence quotient) (assessed using KEDI-WISC (Korean educational Development Institute-Wechsler Intelligence Scale for children)) 70 and lower than 70~3. Patients with a history of neuroleptic malignant syndrome~4. Patients with antipsychotic or alcohol use disorder (abuse, dependence, and/or withdrawal) according to DSM-IV criteria for the past 3 months~5. Patients with a history of allergy or hypersensitivity reaction to aripiprazole~6. Patients with a history of resistance to treatment with antipsychotics~7. Patients who have participated in another clinical study within 1 month prior to screening~8. Patients who have previously taken aripiprazole or participated in a clinical study with aripiprazole

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aripiprazole 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
- 2 (Type: PLACEBO_COMPARATOR): Placebo 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~AT ENROLLMENT:~* Subject must be 18-60 years of age.~* Subject must read and sign a copy of the approved Consent Form~* Female subjects must be using an effective birth control method.~INCLUSION CRITERIA AT DAY -28~* Subject must read and sign a copy of the approved Consent Form~AT CHALLENGE:~* Female subjects must be using an effective birth control method.~* Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to rhinovirus type 39~Exclusion Criteria:~AT ENROLLMENT:~* Current cancer diagnosis or immunosuppressive therapy in the last 6 months~* Any clinically significant abnormalities of the upper respiratory tract~* Any clinically significant acute or chronic respiratory illness~* Any clinically significant bleeding tendency by history~* Hypertension that requires treatment with antihypertensive medications~* History of angina or other clinically significant cardiac disease~* Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study~* History of regular use (more than 3 days in 7) of tobacco products within the preceding two weeks~* History of drug or alcohol abuse in the 6 months preceding the study~EXCLUSION CRITERIA AT DAY -28~* Antibiotic use within 3 months prior to study start~* Female subjects with a positive urine pregnancy screen.~* History of use of probiotics in the preceding 2 weeks.~EXCLUSION CRITERIA AT CHALLENGE:~* Any upper respiratory infection or allergic rhinitis in the two weeks prior to the start of the study~* Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study~* Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold preparation in the two weeks prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Bifidobacterium animalis lactis Bl-04 (Type: EXPERIMENTAL): Bifidobacterium animalis subspecies lactis Bl-04 as powder mixed into drink.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients having elective craniotomy for clipping of unruptured intracranial aneurysm~2. Patients having craniotomy and microvascular decompression for cranial nerve neuralgia~3. Age 18-80~4. ASA I -III~Exclusion Criteria:~1. Patients with a known history of hypersensitivity to Sumatriptan or sulphonamides~2. Patients with a known history of Migraine~3. Patients who is on regular treatment with Sumatriptan~4. Patients with history of Ischemic heart disease - Angina, Myocardial infarction.~5. Patients who had rupture of their intracranial aneurysm.~6. Patients with history of severe liver disease.~7. Patients with history of stroke or uncontrolled hypertension~8. Inability to give informed consent~9. Pregnant patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sumatriptan (Type: EXPERIMENTAL): Subcutaneous injection of sumatriptan (6 mg)
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo (0.9% saline)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Menstrual Blood Stem Cells in Severe Covid-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients whose clinical and laboratory test results have a positive diagnosis of Covid-19.~* Patients who are willing to participate as subjects in the study by signing the informed content.~* Diagnosed with severe pneumonia of COVID: respiratory distress, RR \>30 times/min; resting oxygen saturation of 90% or less; arterial partial pressure of oxygen / oxygen concentration ≤300mmHg; Pulmonary infiltration more than 50% in 24 to 48 hours~* SARS-CoV-2 nucleic acid test was positive.~Exclusion Criteria:~* History of drug reactions or allergies~* Pneumonia caused by bacteria, Mycoplasma, Chlamydia, Legionella, fungi, or other viruses~* Airway obstruction due to lung cancer or unknown factors~* Carcinoid syndrome~* History of epilepsy and long-term use of anticonvulsant drugs during the last 3 years~* History of long-term use of immunosuppressive drugs~* History of chronic respiratory illness that requires long-term oxygen therapy~* The patient is on blood or peritoneal dialysis~* Creatinine clearance \<15 ml / min~* Moderate to severe liver disease (Child-Pugh score\> 12)~* History of deep vein thrombosis (DVT) or pulmonary embolism over the past 3 years~* Being under ECMO or high-frequency oscillatory ventilation support~* Diagnostic of HIV, hepatitis B, and syphilis~* Pregnant or lactating women~* Lack of consciousness and inability to provide informed consent by the patient

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Menstrual blood stem cell secretome group (Type: EXPERIMENTAL): Intravenous Allogeneic Menstrual Blood Stem Cells Secretome injection+Routine treatment
- Control group (Type: PLACEBO_COMPARATOR): Intravenous saline injection (Placebo)+Routine treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The diagnosis of acute pancreatitis accords with the Atlanta criteria in 1992~* Within 3 days from the onset of the disease~* Hemodynamics stable~Exclusion Criteria:~* Decompressive measures and enteral nutrition was performed before admission~* Ileus of lower digestive tract~* Pregnant pancreatitis~* Chronic organs dysfunction~* Immunodeficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Early enteral nutrition (Type: EXPERIMENTAL): The enteral nutrition was started within 48h after admission
- Delayed enteral nutrition (Type: ACTIVE_COMPARATOR): The enteral nutrition was started at the 8th day after admission

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nasal Ocular Reflexes Contribute to Eye Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of grass and/or ragweed allergic rhinitis.~* Positive skin test to grass and/or ragweed antigen.~* Positive response to screening nasal challenge.~Exclusion Criteria:~* Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.~* Pregnant or lactating women.~* Upper respiratory infection within 14 days of study start.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day of the Screening Visit.~* Clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely controlled by current antiepileptic drugs.~* Must have a minimum # of convulsive seizures per 4-week period for past 12 weeks prior to screening.~* All medications or interventions for epilepsy must be stable for at least 4 weeks prior to screening and expected to remain stable throughout the study.~* No cardiovascular or cardiopulmonary abnormality based on ECHO, ECG or physical examination.~* Parent/caregiver is willing and able to be compliant with diary completion, visit schedule and study drug accountability.~Key Exclusion Criteria:~* Pulmonary arterial hypertension.~* Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke.~* Current or past history of glaucoma.~* Moderate or severe hepatic impairment.~* Receiving concomitant therapy with: anorectic agents; monoamine-oxidase inhibitors; medications that act via serotonin including serotonin reuptake inhibitors; atomoxetine, or other centrally-acting noradrenergic agonist; or cyproheptadine.~* Currently receiving or has received stiripentol in the past 21 days prior to Screening.~* Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days.~* Positive result on tetrahydrocannabinol (THC) or cannabidiol (CBD) test at the Screening Visit.~* A clinically significant medical condition,that would interfere with study participation, collection of study data, or pose a risk to the subject.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- ZX008 - 0.8 mg/kg/day (Type: EXPERIMENTAL): ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
- ZX008 - 0.2 mg/kg/day (Type: EXPERIMENTAL): ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
- Matching Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered twice a day (BID) in equally divided doses with food.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent will be obtained from parent(s) or other legally acceptable representative(s), and informed assent from patient (if age appropriate) will be obtained~2. Male or female children ages ≥3 months to \<18 years.~3. Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected or confirmed infection, and expected to require hospitalization until after the end of treatment (EOT) evaluations are completed.~4. If female and has reached menarche, or has reached Tanner stage 3 breast development (even if not having reached menarche), the patient is practicing appropriate birth control or is sexually abstinent.~5. Likely to survive the current illness or hospitalization.~6. Sufficient intravascular access (peripheral or central) to receive study drug.~Exclusion Criteria:~1. History of hypersensitivity reactions to carbapenems, cephalosporins, penicillin, other β-lactam antibiotics.~2. If female, currently pregnant or breast feeding or has a positive serum β-human chorionic gonadotropin (β-hCG) pregnancy test.~3. Receipt of a blood or blood component (e.g., red blood cells, fresh frozen plasma, platelets) transfusion during the 24-hour period before enrolment.~4. BMI outside the range (below the 5th percentile or above the 85th percentile) for height, age, and weight except for children \<2 years of age.~5. Babies born prior to 37 weeks gestation (cohort 4 only).

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- CAZ-AVI (Type: EXPERIMENTAL): This arm will include 4 cohorts. Patients will be stratified by age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete